At least one lesion, not previously irradiated, that can be accurately measured at baseline as >=  mm in the longest diameter (except lymph nodes which must have short axis >=  mm) with computed tomography (CT) or magnetic resonance imaging (MRI) or >=  mm with calipers by clinical exam OR at least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/plain x-ray/clinical exam at baseline and follow up visits
Patients must have radiographically measurable disease (with the exception of neuroblastoma), Measurable disease is defined as the presence of at least one lesion on magnetic resonance imaging (MRI) or computed tomography (CT) scan that can be accurately measured with the longest diameter a minimum of  mm in at least one dimension (CT scan slice thickness no greater than  mm).
Patients must have measurable disease, defined as lesions that can be accurately measure in in  perpendicular diameters with at least one diameter > mm and the other >mm on conventional CT or MRI or mm x  mm by spiral CT.
Measurable lesion; patients are required to have at least one measurable non-bone lesion ?  mm that has not been irradiated\r\n* Measurable metastatic disease documented by radiograph, computed tomography (CT) scan, positron emission tomography (PET)/CT, magnetic resonance imaging (MRI), or physical exam is required; each subject will be required to have at least one measurable lesion that has not been irradiated with a minimum size in at least one diameter of ?  mm for liver lesions, lung, skin, and ?  mm lymph node metastases; biopsy of recurrent site(s) is not required
Patients must have measurable disease, according to Response Evaluation Criteria in Solid Tumors (RECIST) version (v).; measurable disease is defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded for non-nodal lesions) as >=  mm with conventional techniques or as >=  mm with spiral computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam; to be considered pathologically enlarged and measurable, a lymph node must be >= mm in short axis when assessed by CT scan or MRI (CT scan slice thickness recommended to be no greater than  mm)
Patients must have evaluable disease as defined by RECIST . with tumor lesion >  mm by computed tomography (CT) scan or caliper measurement on clinical exam or lymph node >=  mm in short axis
Has measurable disease, defined as at least  lesion that can be accurately measured in at least  dimension (longest diameter to be recorded) with a minimum size of  mm by computerized tomography (CT) scan, except lymph nodes which must have minimum short axis size of  mm (CT scan slice thickness no greater than  mm in both cases). Indicator lesions must not have been previously treated with surgery, radiation therapy, or radiofrequency ablation unless there is documented progression after therapy
Subjects with B cell lymphoma must have measurable disease, defined as at least  lesion that can be accurately measured in at least  dimensions with computed tomography (CT) scan; minimum measurement must be >  mm in the longest diameter and >  mm in the short axis
All patients must have measurable disease as defined by immune-related Response Evaluation Criteria in Solid Tumors (irRECIST); measurable disease is defined as  mm in the longest diameter by computed tomography (CT) or magnetic resonance imaging (MRI) scan (or no less than double the slice thickness) for non- nodal lesions and >=  mm in short axis for nodal lesions,  mm by chest X-ray, a lymph node must be >=  mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than  mm)
Patients may have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension in accordance with RECIST criteria v. . OR non-measurable tumors; NOTE: Non-measurable tumors are small lesions (longest diameter <  mm or pathological lymph nodes with >=  to <  mm short axis); bone lesions, ascites, pleural/pericardial effusions, lymphangitis cutis/pulmonitis, inflammatory breast disease, and abdominal masses (not followed by computed tomography [CT] or magnetic resonance imaging [MRI]) are considered as non-measurable
Patients must have measurable disease and is defined as a lesion that can be accurately measured on the long axis with a minimum size of  mm or a lymph node that can be accurately measured along the short axis of a minimum size of  mm (computed tomography [CT] scan slice thickness can be no greater than  mm)
Para-aortic nodal involvement above the level of the common iliac nodes or L/L (if biopsy proven, PET positive or > mm short axis diameter on CT)
Has measurable disease, defined as at least  lesion that can be accurately measured in at least  dimension (longest diameter to be recorded) with a minimum size of  mm by computerised tomography (CT) scan, except lymph nodes which must have minimum short axis size of  mm (CT scan slice thickness no greater than  mm in both cases). Indicator lesions must not have been previously treated with surgery, radiation therapy, or radiofrequency ablation unless there is documented progression after therapy.
Patients must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm by computed tomography (CT) scan, positron emission tomography (PET)/CT scan, magnetic resonance imaging (MRI) or caliper/ruler measurement by clinical exam; lymph nodes: to be considered pathologically enlarged and measurable, a lymph node must be >=  mm in short axis when assessed by CT scan; lesions that have been radiated in the advanced setting cannot be included as sites of measurable disease unless clear tumor progression has been documented in these lesions since the end of radiation therapy
No evidence of metastatic disease or nodal disease as determined by radionuclide bone scans and computed tomography (CT)/magnetic resonance imaging (MRI); non-pathological lymph nodes must be less than  mm in the short (transverse) axis.
Has measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) with a minimum size of  mm by computed tomography (CT) scan, except lymph nodes which must have minimum short axis size of  mm (CT scan slice thickness no greater than  mm in both cases). Indicator lesions must not have been previously treated with surgery, radiation therapy, or radiofrequency ablation unless there is documented Response Evaluation Criteria in Solid Tumors (RECIST) version . progression in the lesion after such therapy.
For subject with extracranial disease, they must have at least one lesion, not previously irradiated, that can be accurately measured at baseline as >=  mm in the longest diameter (except lymph nodes which must have short axis >=  mm) with computed tomography (CT) or magnetic resonance imaging (MRI) or >=  mm with calipers by clinical exam OR at least one lesion (measurable and/or non-measurable) that can be accurately assessed by CT/MRI/pain x-ray/clinical exam at baseline and follow up visits
Patients with non-measurable or measureable disease are eligible; measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter for non-nodal lesions and short axis for nodal lesions to be recorded) as >=  mm by chest x-ray, as >=  mm with computed tomography (CT) scan, or >=  mm with calipers by clinical exam; malignant lymph nodes, to be considered pathologically enlarged and measurable, must be >=  mm in short axis when assessed by CT scan (CT scan slice thickness recommended to be no greater than  mm); at baseline and in follow-up, only the short axis will be measured and followed\r\n* Tumor lesions that are situated in a previously irradiated area can be considered measurable as long as >=  days has passed since radiation to that area
Patients must have measurable or non-measurable disease by Response Evaluation Criteria in Solid Tumors (RECIST) criteria (version .), with radiologic scans performed within  days of registration; baseline scans can include:\r\n* CT scan or magnetic resonance imaging (MRI) and bone scan OR\r\n* Positron emission tomography (PET)/CT provided the PET/CT is performed with both intravenous (IV) and oral contrast and the CT is acquired with  mm or less slice thickness; if IV contrast administration is contraindicated, patients should have CT scan without contrast and bone scan or MRI and bone scan\r\n* MRI of the brain will be used for baseline assessment and tumor response assessment for CNS lesions\r\n* Patients with CNS progression without systemic progression will be allowed to remain on the protocol; local treatment, radiation, surgery, and stereotactic radiosurgery (SRS) will be allowed while on protocol as deemed necessary by the treating physician\r\n* The baseline imaging method(s) should be used to determine tumor response throughout the course of the study\r\n* Measurable disease: lesions with clearly defined margins that can be accurately measured in at least one diameter (longest diameter to be recorded) with a minimum size of :\r\n**  mm by CT scan (CT scan slice thickness no greater than  mm)\r\n**  mm caliper measurement by clinical exam (lesions which cannot be accurately measured with calipers should be recorded as non-measurable)\r\n**  mm by chest x-ray\r\n** Malignant lymph nodes: to be considered pathologically enlarged and measurable, a lymph node must be >=  mm in short axis when assessed by CT scan; at baseline and in follow-up, only the short axis will be measured and followed\r\n* Non-measurable disease: all other lesions, including small lesions (longest diameter: all other lesions, including small lesions (longest diameter <  mm or pathological lymph nodes with >= to <  mm [short axis]), and masses with margins not clearly defined; lesions that are considered non-measurable include:\r\n** Bone lesions\r\n** Leptomeningeal disease\r\n** Ascites\r\n** Pleural/pericardial effusion\r\n** Inflammatory breast disease\r\n** Abdominal masses that are not confirmed and followed by imaging techniques\r\n** Cystic lesion\r\n** Lymphangitic involvement of skin or lung
Para-aortic nodal involvement above the level of the common iliac nodes or L/L (if biopsy proven, PET positive, or >=  mm short-axis diameter on computed tomography [CT])
at least  melanoma lesion that can be accurately and serially measured in at least  dimensions and for which the longest diameter is ?  mm and with perpendicular diameter ?  mm as measured by contrast-enhanced or spiral computed tomography (CT) scan for visceral or nodal/soft tissue disease. Lymph nodes must measure >  mm in their short axis to be considered measurable by CT scan.
Patients must have measurable disease per RECIST .; measurable lesions are defined as those that can be accurately measured in at least one dimension (longest diameter to be recorded as >=  mm (>=  cm) with computed tomography (CT) scan, magnetic resonance imaging (MRI), or calipers by clinical exam; to be considered pathologically enlarged and measurable, a lymph node must be >=  mm (>= . cm) in short axis
No evidence of metastatic or nodal disease as determined by radionuclide bone scans computed tomography (CT)/MRI; non-pathological lymph nodes must be less than  mm in the short (transverse) axis
At least one measurable metastatic lesion according to Response Evaluation Criteria in Solid Tumors version . (RECIST .) criteria; ascites, pleural effusions, and bone metastases are not considered measurable; minimum indicator lesion size =  mm by helical computed tomography (CT) or =  mm by conventional techniques; pathological nodes must be =  mm by the short axis to be considered measurable
Patients must have measurable disease, as defined by RECIST . criteria: one lesion that can be accurately measured in at least one dimension (longest diameter to be recorded) as >=  mm with spiral computed tomography (CT) scan (CT scan slice thickness no greater than  mm) malignant lymph nodes will be considered measurable if they are >=  mm in short axis
Has measurable disease (at least one lesion, not irradiated within  weeks of study randomisation, with longest diameter more or equal mm (lymph nodes minimum more or equal  mm) with CT or MRI).
At least  measurable breast cancer lesion that is ? mm in one dimension (or ?mm in shortest axis for lymph nodes) by spiral CT scan or by brain MRI
Patients must have measurable disease, i.e., lesions that can be accurately measured in at least  dimension (longest dimension in the plane of measurement is to be recorded) with a minimum size of  mm by computed tomography (CT) scan (CT scan slice thickness no greater than  mm)
Size: Lesion can be accurately measured in at least one dimension with a longest diameter ? mm, or for lymph nodes ? mm short axis. Lesions meeting size criteria will be considered measurable.
No evidence of metastatic disease as determined by radionuclide bone scans and computed tomography (CT)/MRI; lymph nodes must be less than  mm in the short (transverse) axis
As measured by conventional high spatial resolution MRI, the minimum diameter of the primary lesion (short axis) should be at least  mm
Has measurable disease defined as ? lesion that can be accurately measured in ? dimensions with spiral computed tomography (CT) scan or combined CT/positron emission tomography (PET) scan. Minimum measurement must be > mm in the longest diameter or > mm in the short axis.